Cellular Reprogramming & Rejuvenation

Genflow Biosciences announced that its SLAB gene therapy trial in ageing dogs has met its primary endpoint, and it is now in talks with major animal health companies about a licensing deal. EnergyPathways has appointed Jacobs as engineering and regulatory partner for its MESH energy storage project in the Irish Sea, moving toward a key Ofgem funding submission. Itaconix is targeting a doubling of revenue to $30 million in the medium term, after half-year revenue jumped 72% on strong detergent demand. Gaming Realms says it is well placed to keep growing despite a UK tax hike hitting margins, with core content licensing revenue up 12% in the first half. Total Graphite reports that fresh drilling in Madagascar has strengthened the case for restarting mining at Vatomina, with one hole returning 19 metres at 3.3% graphite. 80 Mile has agreed indicative terms for a £61.5 million all-share takeover by Nasdaq-listed Greenland Energy, representing a near-47% premium to its share price.

Several biotechs have landed sizable funding rounds even as investors remain selective. Ollin Biosciences announced a $330 million series B round co-led by TCGX and Arch Venture Partners to advance its next-generation VEGF/Ang2 bispecific antibody OLN324 for diabetic macular edema and wet age-related macular degeneration. Beeline Medicines, a Bristol Myers Squibb spinout backed by Bain Capital, emerged from stealth with $300 million to develop five in-licensed immunology drugs, including the phase 2 lupus pill afimetoran. New Limit closed a $435 million series C round backed by Founders Fund and Lilly Ventures, reaching an estimated $3.1 billion valuation, and plans to begin clinical trials next year for its epigenetic reprogramming therapy targeting liver aging.